Formulary Chapter 6: Endocrine system - Full Chapter
|
|
Chapter Links... |
NICE NG28: Type 2 diabetes in adults: management |
DVLA guidance |
NICE Guidance on prescribing |
Details... |
06.01 |
Drugs used in diabetes |
|
|
|
|
|
|
06.01.01 |
Insulins |
|
|
|
|
06.01.01.01 |
Short-acting insulins |
|
|
Insulin
|
Formulary
|
- Actrapid
- Humulin S
- Insuman Rapid
|
|
Insulin (Humulin R 500 units in 1mL®)
|
Formulary
|
|
|
Insulin Aspart
|
Formulary
|
- Fiasp
- Fiasp FlexTouch
- Fiasp Penfill
- NovoRapid
- NovoRapid FlexPen
- NovoRapid FlexTouch
- NovoRapid Penfill
- Trurapi
|
|
Insulin Glulisine
|
Formulary
|
BRANDS
|
For your patients with diabetes who are currently prescribed Apidra®: A guide on how to use Apidra®.
|
06.01.01.01 |
Soluble Insulin |
|
|
06.01.01.01 |
Rapid Acting Insulin Analogues |
|
|
06.01.01.01 |
Ultra-Rapid acting insulin analogues |
|
|
06.01.01.01 |
Short-acting human insulin analogues |
|
|
Insulin lispro
|
Formulary
|
BRANDS
|
|
06.01.01.02 |
Intermediate- and long-acting insulins |
|
|
Insulin glargine (Semglee®)
|
First Choice
|
First line insulin for new patients initiated on insulin glargine 100units/ml and existing patients on Lantus
|
NICE NG17: Type 1 diabetes in adults: diagnosis and management
|
Insulin Detemir
|
Formulary
|
- Levemir FlexPen
- Levemir InnoLet
- Levemir Penfill
|
|
INSULIN GLARGINE
|
Formulary
|
- Abasaglar KwikPen
- Lantus
- Toujeo
- Toujeo DoubleStar
|
NICE NG17: Type 1 diabetes in adults: diagnosis and management
For your patients who are currently prescribed Lantus®: A guide on how to use Lantus®.
For your patients with diabetes who are currently prescribed Lantus ®: A step-by-step guide on how to use Lantus® SoloStar.
For your patients with diabetes who are currently prescribed Toujeo® DoubleStar: A guide on how to use Toujeo® DoubleStar.
For your patients with diabetes who are currently prescribed Toujeo® SoloStar: A guide on how to use Toujeo ® SoloStar.
|
Insulin Degludec (Tresiba Flextouch ®) (200units/ml)
|
Formulary
|
- Tresiba FlexTouch 200units/ml
Type I Diabetes
Type II Diabetes
|
|
Insulin Degludec (Tresiba®)
|
Formulary
|
- Tresiba FlexTouch 100units/ml
- Tresiba Penfill 100units/ml
|
|
Insulin degludec/liraglutide
|
Formulary
|
|
|
Isophane Insulin
|
Formulary
|
- Humulin I
- Humulin I KwikPen
- Insulatard
- Insulatard InnoLet
- Insulatard Penfill
- Insuman Basal
- Insuman Basal SoloStar
|
For your patients with diabetes who are currently prescribed Insuman® Basal: A step-by-step guide on how to use Insuman® Basal SoloStar.
|
06.01.01.02 |
Biphasic insulins |
|
|
Biphasic Insulin Aspart
|
Formulary
|
BRANDS
- NovoMix 30 FlexPen
- NovoMix 30 Penfill
|
|
Biphasic Insulin Lispro
|
Formulary
|
BRANDS
- Humalog Mix25
- Humalog Mix25 KwikPen
- Humalog Mix50
- Humalog Mix50 KwikPen
|
|
Biphasic Isophane Insulin
|
Formulary
|
BRANDS
- Humulin M3
- Humulin M3 KwikPen
|
|
Biphasic Isophane Insulin (Insuman Comb® )
|
Formulary
|
Insuman comb 25
Insuman comb 50
|
|
Insulin Lispro
|
Formulary
|
- Admelog
- Humalog 100units/ml
- Humalog KwikPen
- Lyumjev
- Lyumjev KwikPen
- Lyumjev Junior KwikPen
|
|
06.01.01.02 |
Intermediate Acting Insulin |
|
|
06.01.01.02 |
Long Acting Insulin Analogues |
|
|
06.01.01.03 |
Hypodermic equipment |
|
|
Insulin Pen Needles (Microdot MAX safety pen needles 5mm/30g ®)
|
Formulary
|
There are used primarily to protect any individuals administering insulin as a third party
|
|
Injection Devices
|
Formulary
|
- AllStar Pro hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-80 units
- Autopen
- Autopen 24 hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-21 units
- Autopen 24 hypodermic insulin injection pen reusable for 3ml cartridge 2 unit dial up / range 2-42 units
- Autopen Classic hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-21 units
- Autopen Classic hypodermic insulin injection pen reusable for 3ml cartridge 2 unit dial up / range 2-42 units
- HumaPen Ergo
- HumaPen Luxura
- HumaPen Luxura HD hypodermic insulin injection pen reusable for 3ml cartridge 0.5 unit dial up / range 1-30 units
- HumaPen Savvio hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-60 units
- JuniorSTAR hypodermic insulin injection pen reusable for 3ml cartridge 0.5 unit dial up / range 1-30 units
- NovoPen
- NovoPen 5 hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-60 units
- NovoPen Echo hypodermic insulin injection pen reusable for 3ml cartridge 0.5 unit dial up / range 0.5-30 units
- OptiPen Pro 1
- mhi-500
|
|
06.01.01.03 |
Needles |
|
|
Insulin Pen Needles (BD Viva 4mm/32g pen needles )
|
Formulary
|
|
|
Insulin Pen Needles (BD Viva 5mm/31g pen needles )
|
Formulary
|
|
|
Insulin Pen Needles (GlucoRx Carepoint 5mm/31g pen needles )
|
Formulary
|
|
|
Insulin Pen Needles (Insupen 4mm/32g pen needles )
|
Formulary
|
|
|
Insulin Pen Needles (Insupen 5mm/31g pen needles )
|
Formulary
|
|
|
Needle free administration device
|
Formulary
|
BRANDS
- Injex 10ml vial adaptor pack
- Injex 4 monthly refill pack
- Injex ampoule pack
- Injex starter set
- InsuJet 10ml vial adaptor pack 5 pieces
- InsuJet 3ml cartridge adaptor pack 5 pieces
- InsuJet nozzle pack 5 pieces
- InsuJet starter set
|
|
Omnican fine
|
Formulary
|
|
|
Penfine classic
|
Formulary
|
|
|
06.01.01.03 |
Lancets |
|
|
06.01.02 |
Antidiabetic drugs |
|
|
06.01.02.01 |
Sulphonyureas |
|
|
Gliclazide (Oral presentations)
|
Formulary
|
- Tablets
- Modified Release Tablets
Check OptimiseRx for most cost effective brand
|
NG28 :Type 2 diabetes in adults: management
|
Tolbutamide
|
Formulary
|
|
|
Glimepiride
|
Formulary
|
|
|
06.01.02.02 |
Biguanides |
|
|
Metformin (Powder)
|
Second Choice
|
Patients with swallowing difficulties
|
NICE NG28: Type 2 diabetes in adults: management
|
Metformin (Oral Solution SF)
|
Second Choice
|
For patients with swallowing difficulties only.
Tablets more cost effective.
|
NICE NG28: Type 2 diabetes in adults: management
|
Metformin (Tablets)
|
Formulary
|
|
NICE NG28: Type 2 diabetes in adults: management
|
Metformin (M/R tablets)
|
Formulary
|
Check Optimise Rx for most cost effective brand
|
NICE NG28: Type 2 diabetes in adults: management
|
06.01.02.03 |
Other antidiabetic drugs |
|
|
Alogliptin with Metformin (Vipdomet®)
|
Formulary
|
A variety of combinations tablets (dual therapies) of oral diabetes medication can be prescribed and are available in the Drug Tariff.
Overall, they may improve compliance in patients, however some combinations would then not allow the flexibility in dosing that is required for diabetes management and in some cases increase the tablet burden. There are specific sick-day rules related to stopping certain medication which would be further complicated where they are not prescribed in their separate formulations.
Furthermore, for the overall health economy not all combination therapies are cost-effective and this will be increasingly so as the patents expire over the near future.
There are some combination therapies that are not recommended in the oral guidance and clinicians are guided to review and discuss these with patients as part of shared -care decision making.
There are complexities also around the lack of licensing of dual therapies in specific cohorts of patients, related to prescribing for the indication of heart failure or renal disease, making this a complex area for prescribing in primary care.
|
|
Canagliflozin/Metformin (Vokanamet®)
|
Formulary
|
|
|
Dapagliflozin / Metformin (Xigduo®)
|
Formulary
|
|
|
Empagliflozin / Metformin (Synjardy ®)
|
Formulary
|
|
|
Linagliptin/ Metformin (Jentadueto ®)
|
Formulary
|
A variety of combinations tablets (dual therapies) of oral diabetes medication can be prescribed and are available in the Drug Tariff.
Overall, they may improve compliance in patients, however some combinations would then not allow the flexibility in dosing that is required for diabetes management and in some cases increase the tablet burden. There are specific sick-day rules related to stopping certain medication which would be further complicated where they are not prescribed in their separate formulations.
Furthermore, for the overall health economy not all combination therapies are cost-effective and this will be increasingly so as the patents expire over the near future. There are some combination therapies that are not recommended in the oral guidance and clinicians are guided to review and discuss these with patients as part of shared -care decision making.
There are complexities also around the lack of licensing of dual therapies in specific cohorts of patients, related to prescribing for the indication of heart failure or renal disease, making this a complex area for prescribing in primary care
|
|
Sitagliptin and Metformin
|
Formulary
|
A variety of combinations tablets (dual therapies) of oral diabetes medication can be prescribed and are available in the Drug Tariff.
Overall, they may improve compliance in patients, however some combinations would then not allow the flexibility in dosing that is required for diabetes management and in some cases increase the tablet burden. There are specific sick-day rules related to stopping certain medication which would be further complicated where they are not prescribed in their separate formulations.
Furthermore, for the overall health economy not all combination therapies are cost-effective and this will be increasingly so as the patents expire over the near future. There are some combination therapies that are not recommended in the oral guidance and clinicians are guided to review and discuss these with patients as part of shared -care decision making.
There are complexities also around the lack of licensing of dual therapies in specific cohorts of patients, related to prescribing for the indication of heart failure or renal disease, making this a complex area for prescribing in primary care
|
|
06.01.02.03 |
DPP-4 inhibitors |
|
|
06.01.02.03 |
Alpha glucosidase inhibitors |
|
|
06.01.02.03 |
GLP-1 mimetics |
|
|
06.01.02.03 |
DPP4 inhibitors (gliptins) |
|
|
Sitagliptin
|
First Choice
|
To be used in line with NICE
First line treatment option where a DPP-4 inhibitor is indicated.
No significant clinical benefit when used in combination with Insulin – avoid using together
|
MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
|
Alogliptin (Vipidia®)
|
Formulary
|
In line with NICE No significant clinical benefit when used in combination with Insulin – avoid using together
|
MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
|
Linagliptin
|
Formulary
|
In line with NICE Linagliptin has no significant clinical benefit or renoprotective effect in patients with CKD.
Sitagliptin should be used first line at the appropriate renal dose where a DPP4 inhibitor is indicated
No significant clinical benefit when used in combination with Insulin – avoid using together
|
MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
|
06.01.02.03 |
SGLT2 inhibitors |
|
|
06.01.02.03 |
GLP1 agonists |
|
|
Dulaglutide (Trulicity®)
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
|
How to use Trulicity Pen - Video
NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
|
Exenatide ( prolonged-release suspension for injection)
|
Formulary
|
- prolonged-release suspension for injection
|
NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
|
Liraglutide (Saxenda®)
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
• Injection • For weight loss/ obesity • Use according to NICE guidance
The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place.
Prescribe by brand (Saxenda ®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes
|
NICE TA664: Liraglutide for managing overweight and obesity
NICE NG28: Type 2 diabetes in adults: management
|
Liraglutide (Victoza®)
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
Use according to NICE guidance
For the treatment of type 2 diabetes ONLY
THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity.
|
NICE TA664: Liraglutide for managing overweight and obesity
How to use Victoza Pen - Video
NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
|
Lixisenatide
|
Formulary
|
|
|
Semaglutide (Rybelsus®▼) (Oral Tablets)
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
Rybelsus is a tablet for once-daily oral use but has special administration directions:
- It must be taken on an empty stomach at any time of the day.
- Patients are required to wait at least 30 minutes before eating/drinking or taking other oral medicinal products. Waiting less than 30 minutes decreases absorption.
- It should be swallowed whole with a sip of water (up to half a glass of water equivalent to 120 ml).
|
|
Semaglutide (Wegovy ®)
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on Prescribing; manufacturer advises to record the brand name and batch number after each administration.
The use of semaglutide for this indication is restricted to prescribing by commissioned clinics in secondary care by a consultant led specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place.
Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes.
|
|
06.01.02.03 |
Meglitinides |
|
|
Repaglinide
|
Formulary
|
|
|
06.01.02.03 |
SGL2 inhibitors |
|
|
Canagliflozin
|
Formulary
|
For treating Type 2 diabetes in line with NICE, and chronic kidney disease.
Do not use SGLT2-inhibitors in patients with T1DM, regardless of CKD and/or heart failure status due to risk of DKA (diabetic ketoacidosis)
|
MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
MHRA Alert: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
MHRA: Canagliflozin (Invokana, Vokanamet): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients
MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
|
Dapagliflozin
|
Formulary
|
for treating Type 2 diabetes and chronic kidney disease in line with NICE
Do not use SGLT2-inhibitors in patients with T1DM, regardless of CKD and/or heart failure status due to risk of DKA (diabetic ketoacidosis)
Treatment of all grades of symptomatic heart failure
SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis
MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
|
MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
NICE TA775: Dapagliflozin for treating chronic kidney disease
NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
MHRA Alert: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
|
Empagliflozin
|
Formulary
|
For treating type 2 diabetes Do not use SGLT2-inhibitors in patients with T1DM, regardless of CKD and/or heart failure status due to risk of DKA (diabetic ketoacidosis)
treatment of all grades of symptomatic heart failure
SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis
MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
|
MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
MHRA Alert: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
|
Empagliflozin/Linagliptin
|
Formulary
|
|
|
Ertugliflozin
|
Formulary
|
In line with NICE
Do not use SGLT2-inhibitors in patients with T1DM, regardless of CKD and/or heart failure status due to risk of DKA (diabetic ketoacidosis)
|
MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
MHRA Alert: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
|
06.01.02.03 |
Other |
|
|
Capsaicin
|
Formulary
|
|
|
Duloxetine
|
Formulary
|
Prescribe generically as 30mg & 60mg.
90 and 120mg not cost-effective
|
|
Irbesartan
|
Formulary
|
|
|
Losartan Potassium
|
Formulary
|
|
|
06.01.02.03 |
Thiazolidinediones |
|
|
Pioglitazone
|
Formulary
|
|
MHRA: Insulin combined with pioglitazone: risk of cardiac failure
MHRA: Pioglitazone: risk of bladder cancer
NICE NG28: Type 2 diabetes in adults: management
|
06.01.02.05 |
Glucagon-like peptide-1 receptor agonists - once weekly |
|
|
06.01.02.07 |
Other antidiabetic drugs |
|
|
06.01.03 |
Diabetic ketoacidosis |
|
|
06.01.04 |
Treatment of hypoglycaemia |
|
|
Glucagon (GlucaGen® HypoKit)
|
Formulary
|
|
|
GlucoGel®
|
Formulary
|
|
|
Glucose
|
Formulary
|
|
|
Glucose (oral gel)
|
Formulary
|
|
|
Glucose (Solution for infusion)
|
Formulary
|
|
|
06.01.04 |
Chronic hypoglycaemia |
|
|
06.01.05 |
Treatment of diabetic nephropathy and neuropathy |
|
|
06.01.05 |
Diabetic nephropathy |
|
|
06.01.05 |
Diabetic neuropathy |
|
|
Lisinopril
|
Formulary
|
|
|
06.01.06 |
Diagnostic and monitoring agents for diabetes mellitus |
|
|
Continuous Glucose Monitoring (Dexcom One Sensor ®)
|
Formulary
|
In line with NHSE criteria, see annex A in the following link: https://www.blackcountryformulary.nhs.uk/docs/files/National-arrangements-for-funding-of-relevant-diabetes-patients-June-2020-Updated-final.pdf
|
Flash Glucose Monitoring: National Arrangements for Funding of Relevant Diabetes Patients
|
Glucose interstitial fluid detection sensors (FreeStyle Libre 2 Sensor ® )
|
Formulary
|
in Type I Diabetes
in Type II Diabetes in line with RMOC criteria
|
|
Ketones Test Strips (FreeStyle Optium beta-ketone testing strips®)
|
Formulary
|
- FreeStyle Optium beta-ketone testing strips
|
|
Ketones Test Strips (Glucofix Tech beta-ketone Sensor testing strips ®)
|
Formulary
|
|
|
Ketones Test Strips (KetoSens testing strips ®)
|
Formulary
|
|
|
Urinalysis Glucose strips Medi-Test Glucose®
|
Formulary
|
|
|
Urinalysis test strips Diastix®
|
Formulary
|
|
|
Urine Protein strips (Albustix®)
|
Formulary
|
in Primary Care
Secondary care to discuss with Pathology
|
|
Urine Protein strips Medi Test Protein 2®
|
Formulary
|
|
|
06.01.06 |
Blood glucose monitoring |
|
|
Test strips
|
Formulary
|
BRANDS-Use in line with local guidance
- CareSens PRO testing strips
- Contour Next testing strips
- Contour Plus testing strips
- Instant testing strips
- TEE2 testing strips
- WaveSense JAZZ Duo testing strips
- WaveSense JAZZ testing strips
|
|
Test strips
|
Formulary
|
BRANDS
- Aviva testing strips
- FreeStyle Optium testing strips
- On Call Extra testing strips
|
|
06.01.06 |
Urinalysis |
|
|
06.01.06 |
Oral glucose tolerance test |
|
|
06.01.06 |
Blood glucose meters for adults with type 2 diabetes |
|
|
06.01.06 |
Blood glucose meters for children and adults with type 1 diabetes |
|
|
06.01.06 |
Blood glucose meters for patients on continuous insulin infusion pump |
|
|
06.01.06 |
Blood glucose meters for patients with dexterity problems |
|
|
06.01.06 |
Talking blood glucose meters |
|
|
06.02 |
Thyroid and Antithyroid drugs |
|
|
Propranolol (oral solution)
|
Formulary
|
For Paediatric use
|
|
Propranolol
|
Formulary
|
|
|
06.02.01 |
Thyroid hormones |
|
|
Levothyroxine
|
Formulary
|
|
|
Liothyronine (capsules )
|
Formulary
|
|
Items which should not be routinely prescribed in primary care: Guidance for ICB
Patient Information: Changes to liothyronine prescribing
|
Liothyronine (powder for solution for injection)
|
Formulary
|
|
Items which should not be routinely prescribed in primary care: Guidance for ICB
Patient Information: Changes to liothyronine prescribing
|
Metoprolol Tartrate
|
Formulary
|
|
|
06.02.02 |
Antithyroid drugs |
|
|
Carbimazole
|
Formulary
|
Counselling: warn patient to tell doctor immediately if sore throat, mouth ulcers, bruising, fever, malaise or non-specific illness develops
|
|
Propylthiouracil
|
Formulary
|
|
|
Iodine and Iodide
|
Formulary
|
|
|
Potassium iodate (85mg)
|
Formulary
|
|
|
Potassium iodide
|
Formulary
|
|
|
Aqueous iodine (oral solution)
|
Formulary
|
Hospital use only.
|
|
06.03 |
Corticosteroids |
|
|
Prednisolone
|
Formulary
|
|
|
06.03.01 |
Replacement therapy |
|
|
Fludrocortisone Acetate
|
Formulary
|
|
UKMI Q&A: Are adults taking corticosteroids for adrenal insufficiency at risk of osteoporosis?
|
06.03.02 |
Glucocorticoid therapy |
|
|
Betamethasone
|
Formulary
|
|
|
Dexamethasone
|
Formulary
|
|
|
DEXAMETHASONE PHOSPHATE INJECTION
|
Formulary
|
|
|
Hydrocortisone
|
Formulary
|
- SODIUM SUCCINATE
- SODIUM PHOSPHATE
|
|
Hydrocortisone (Oral presentations)
|
Formulary
|
|
|
06.03.02 |
Disadvantages of corticosteroids |
|
|
06.03.02 |
Use of corticosteroids |
|
|
06.03.02 |
Pregnancy and breastfeeding |
|
|
06.03.02 |
Administration |
|
|
06.03.02 |
Withdrawal of corticosteroids |
|
|
06.04 |
Sex hormones |
|
|
Estradiol/Medroxyprogesterone
|
Second Choice
|
|
|
Estradiol/Norethisterone (Oral presentations)
|
Second Choice
|
2nd line to patches
https://pcwhf.co.uk/wp-content/uploads/2021/02/Prescribing-HRT-3.pdf
|
|
Femoston Conti ®
|
Second Choice
|
|
|
Femoston Sequential ®
|
Second Choice
|
|
|
Clonidine Hydrochloride
|
Formulary
|
|
|
Estradiol 10mg (Vagifem®, Vagirux®) (Pessary)
|
Formulary
|
Pessary
|
|
Estradiol 1mg /2mg (Tablets)
|
Formulary
|
|
|
Estradiol hemihydrate (lenzetto 153 mg/spray ®)
|
Formulary
|
|
|
Estradiol/dydrogesterone
|
Formulary
|
|
|
ESTRIOL 0.01% Cream ( 0.01% Cream)
|
Formulary
|
|
|
EVOREL SEQUI PATCH
|
Formulary
|
|
|
NORETHISTERONE (5mg Tabs)
|
Formulary
|
|
|
Progynova TS patch
|
Formulary
|
|
|
Sandrena gel
|
Formulary
|
|
|
Tibolone (Livial®) (Tablets)
|
Formulary
|
|
|
Trisequens ® (Tablets)
|
Formulary
|
|
|
Oestrogel®
|
Formulary
|
|
|
06.04.01 |
Female sex hormones and their modulators |
|
|
06.04.01.01 |
Oestrogens and HRT |
|
|
Evorel Conti® (Patch)
|
First Choice
|
|
|
Evorel Sequi® (Patch)
|
First Choice
|
|
|
Evorel® (Patch)
|
First Choice
|
|
|
Femseven Conti® (Patch)
|
Second Choice
|
|
|
Femseven Sequi® (Patch)
|
Second Choice
|
2nd line to Evorel Sequi®
|
|
COMBINED CYCLICAL HRT
|
Formulary
|
BRANDS
|
|
Elleste Solo
|
Formulary
|
|
|
Elleste-Duet Conti® (Tablets)
|
Formulary
|
|
|
Clinorette® (Tablets)
|
Formulary
|
|
|
Estraderm MX® (Patches)
|
Formulary
|
|
|
Estradot® (Patches)
|
Formulary
|
|
|
Estriol® 0.01% (Cream)
|
Formulary
|
|
|
Femseven ® (Patch)
|
Formulary
|
|
|
Kliofem® (Tablets)
|
Formulary
|
|
|
Kliovance®
|
Formulary
|
|
|
Lubion® (Injection)
|
Formulary
|
Fertility use only
|
|
Novofem® (Tablets)
|
Formulary
|
|
|
Ovestin ® (Cream)
|
Formulary
|
|
|
Premarin® (Tablets)
|
Formulary
|
|
|
Premique® low dose (Tablets)
|
Formulary
|
|
|
Tridestra® (Tablets)
|
Formulary
|
|
|
Zumenon® (Tablets)
|
Formulary
|
|
|
Indivina® (Tablets)
|
Formulary
|
|
|
Premique® modified release (Tablets)
|
Formulary
|
|
|
Progynova®
|
Formulary
|
Progynova® 1mg and 2mg tablets
|
|
Climanor®
|
Formulary
|
|
|
06.04.01.01 |
Hormone replacement therapy |
|
|
|
06.04.01.01 |
Ethinylestradiol |
|
|
Ethinylestradiol (Tablets)
|
Formulary
|
|
|
06.04.01.01 |
Raloxifene |
|
|
Raloxifene
|
Formulary
|
|
NICE TA 160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
|
06.04.01.01 |
Oestrogen only tablets |
|
|
06.04.01.01 |
Oestrogens and progestogen sequential combined therapy |
|
|
06.04.01.01 |
Continuous combined therapy |
|
|
06.04.01.01 |
Gonadomimetic |
|
|
06.04.01.01 |
Selective oestrogen modulator |
|
|
06.04.01.02 |
Progestogens |
|
|
Medroxyprogesterone Acetate (Climanor®)
|
Formulary
|
|
|
Medroxyprogesterone Acetate (Depo -Provera®)
|
Formulary
|
|
|
Medroxyprogesterone Acetate (Provera®)
|
Formulary
|
|
|
Medroxyprogesterone Acetate (Sayana press®)
|
Formulary
|
Suitable for self injection in patients who have had appropriate tranining
|
|
Progesterone (Pessary)
|
Formulary
|
BRANDS
- Cyclogest pessary
- Lutigest pessary
|
|
Progesterone (micronised) (Utrogestan ®)
|
Formulary
|
|
|
|
06.04.02 |
Male sex hormones and antagonists |
|
|
Testosterone (Sustanon 250®) (Injection)
|
Formulary
|
|
|
Testosterone gel
|
Formulary
|
|
|
Testosterone Propionate
|
Formulary
|
|
|
Testosterone undecanoate (Nebido®) (Injection)
|
Formulary
|
|
|
06.04.02 |
Anti-androgens |
|
|
Finasteride (5mg Tablets)
|
Formulary
|
|
|
Dutasteride (Avodart®)
|
Formulary
|
|
|
Cyproterone acetate
|
Formulary
|
BRANDS
|
|
06.04.02 |
Dutasteride and finasteride |
|
|
06.04.03 |
Anabolic steroids |
|
|
06.04.04 |
Gender dysphoria |
|
|
|
|
|
06.05 |
Hypothalamic and pituitary hormones and anti-oestrogens |
|
|
Choriogonadotropin Alfa (Ovitrelle®)
|
Formulary
|
|
|
Clomifene citrate
|
Formulary
|
|
|
Demeclocycline (Capsules)
|
Formulary
|
Treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable
|
|
Desmopressin (oral lyophilisate)
|
Formulary
|
Paediatric Nocturnal enuresis
Diabetes Insipidus
|
|
Desmopressin (nasal spray)
|
Formulary
|
Diabetes Insipidus
|
|
Desmopressin (solution for Injection)
|
Formulary
|
|
|
Desmopressin (Desmotabs®)
|
Formulary
|
Primary Nocturnal enureis -Paediatrics
|
|
GONADORELIN
|
Formulary
|
HRF - Red
Powder For - Red
|
|
Human Chorionic Gonadotrophin
|
Formulary
|
HUMAN MENOPAUSAL GONADOTROPHINS - Red
HUMAN MENOPAUSAL GONADOTROPHINS / Menogon - Red
|
|
OCTREOTIDE
|
Formulary
|
Olatuton - Red
Sandostatin - Red
Sandostatin LAR - Red
|
|
TERLIPRESSIN
|
Formulary
|
Glypressin - Red
|
|
TETRACOSACTIDE
|
Formulary
|
BRANDS
- Synacthen
- Synacthen Depot
|
|
THYROTROPIN ALFA (Thyrogen®)
|
Formulary
|
|
|
VASOPRESSIN
|
Formulary
|
Argipressin - Red
Pitressin - Red
|
|
06.05.01 |
Hypothalamic and anterior pituitary hormones and anti-oestrogens |
|
|
06.05.01 |
Anti-oestrogens |
|
|
06.05.01 |
Anterior pituitary hormones |
|
|
Somatropin (injection)
|
Formulary
|
Genotropin GoQuick powder/solvent for |
Genotropin MiniQuick powder/solvent for injection |
Genotropin powder/solvent for injection |
Humatrope powder/solvent for injection |
Norditropin FlexPro |
Norditropin NordiFlex |
Norditropin SimpleXx |
NutropinAq |
Omnitrope |
Omnitrope SurePal |
Saizen |
Saizen powder/solvent for injection |
Zomacton powder/solvent for injection |
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
NICE TA64: Growth hormone deficiency (adults) - human growth hormone
|
06.05.01 |
Gonadotrophins |
|
|
06.05.01 |
Growth Hormone |
|
|
06.05.01 |
Growth hormone receptor antagonists |
|
|
06.05.01 |
Thyrotropin |
|
|
06.05.01 |
Hypothalmic hormones |
|
|
06.05.02 |
Posterior pituitary hormones and antagonists |
|
|
06.05.02 |
Posterior pituitary hormones |
|
|
06.05.02 |
Antidiuretic hormone antagonists |
|
|
Tolvaptan (Jinarc® )
|
Formulary
|
|
NICE TA358:Tolvaptan for treating autosomal dominant polycystic kidney disease
|
Tolvaptan (Samsca®)
|
Formulary
|
|
|
06.06 |
Drugs affecting bone metabolism |
|
|
Calcitriol
|
Second Choice
|
|
|
Disodium Pamidronate
|
Formulary
|
|
MHRA: Bisphosphonates: atypical femoral fractures
|
Alendronic Acid
|
Formulary
|
|
MHRA: Bisphosphonates: atypical femoral fractures
NICE TA464: Bisphosphonates for treating osteoporosis
TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
|
CALCITONIN
|
Formulary
|
CALCITONIN (SALMON)/SALCATONIN - Red
CALCITONIN SALMON/ CALCITONIN - Red
|
|
Ibandronic acid (50mg tabs)
|
Formulary
|
Dudley
Sandwell
ESCA Sandwell only
Walsall
Wolverhampton
|
ESCA: Ibandronic acid 50mg-Sandwell only
MHRA: Bisphosphonates: atypical femoral fractures
|
Ibandronic acid (Injection)
|
Formulary
|
|
MHRA: Bisphosphonates: atypical femoral fractures
|
Ibandronic acid (150mg tabs )
|
Formulary
|
|
MHRA: Bisphosphonates: atypical femoral fractures
|
PAMIDRONATE DISODIUM
|
Formulary
|
|
|
RISEDRONATE SODIUM 30mg
|
Formulary
|
|
|
ROMOSOZUMAB
|
Formulary
|
Evenity - Red
|
NICE TA 791: Romosozumab for treating severe osteoporosis
|
Sodium Clodronate (Calsteon®, Loron 520® )
|
Formulary
|
Dudley
Sandwell
ESCA- Sandwell
Walsall
Wolverhampton
|
ESCA: Sodium clodronate-Sandwell only
MHRA: Bisphosphonates: atypical femoral fractures
|
Teriparatide
|
Formulary
|
Red - Forsteo
Red - Movymia
Red - Terrosa
|
NICE TA161: Osteoporosis - secondary prevention (including Teriparatide)
|
Zoledronic acid
|
Formulary
|
Red - Aclasta
Red - Zometa
|
MHRA: Bisphosphonates: atypical femoral fractures
NICE TA464: Bisphosphonates for treating osteoporosis
|
|
|
|
|
06.06 |
Osteoporosis |
|
|
06.06.01 |
Calcitonin and parathyroid hormone |
|
|
Calcitonin (salmon) / Salcatonin
|
Formulary
|
Injection
Nasal spray
For hospital use only
|
NICE TA161: Osteoporosis - secondary prevention (including strontium ranelate)
|
06.06.02 |
Bisphosphonates and other drugs affecting bone metabolism |
|
|
|
|
|
06.06.02 |
Bisphosphonates |
|
|
Alendronic acid (Binosto®) (effervescent tablets)
|
Third Choice
|
|
MHRA: Bisphosphonates: atypical femoral fractures
NICE TA464:Bisphosphonates for treating osteoporosis
|
Etidronate disodium (tablets)
|
Formulary
|
In line with NICE
|
MHRA; Bisphosphonates: atypical femoral fractures
NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
|
|
06.06.02 |
Denosumab |
|
|
Denosumab (Prolia®)
|
Formulary
|
Dudley
Sandwell
ESCA-Denosumab-Sandwell only
Walsall
Wolverhampton
with RiCaD
Wolverhampton only
|
ESCA: Denosumab (Prolia)-Sandwell only
NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
|
Denosumab (Xgeva®)
|
Formulary
|
For specialist use only in line with NICE TA265
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance (TA265 )
|
06.06.02 |
Strontium renelate |
|
|
Strontium ranelate
|
Formulary
|
|
|
06.07 |
Other endocrine drugs |
|
|
Bromocriptine
|
Formulary
|
|
|
Cabergoline
|
Formulary
|
Amber Recommended - Cabaser
Amber Recommended - Dostinex
|
MHRA cabergoline
|
Danazol
|
Formulary
|
Off label use for hereditary angiodema
|
|
Ketoconazole (Oral)
|
Formulary
|
|
|
LEUPRORELIN ACETATE
|
Formulary
|
Amber Initiation - Prostap 3 DCS
Amber Initiation - Prostap SR DCS
|
|
Metyrapone (Metopirone®)
|
Formulary
|
|
|
Quinagolide (Norprolac®)
|
Formulary
|
|
|
RELUGOLIX/ ESTRADIOL/ NORETHISTERONE ACETATE
|
Formulary
|
|
|
TAMOXIFEN (Oral presentations)
|
Formulary
|
|
|
TRIPTORELIN (Salvacyl)
|
Formulary
|
|
|
TRIPTORELIN (Decapeptyl SR)
|
Formulary
|
|
|
06.07.01 |
Bromocriptine and other dopaminergic drugs |
|
|
06.07.02 |
Drugs affecting gonadotrophins |
|
|
|
06.07.02 |
Gonadorelin analogues |
|
|
Goserelin
|
Formulary
|
BRANDS
|
CKS guideline: Management of confirmed endometriosis- Secondary Care treatments
|
Leuprorelin (Prostap 3 DCS®)
|
Formulary
|
|
CKS guideline: Management of confirmed endometriosis - Secondary Care treatments
|
Leuprorelin (Prostap SR DCS®)
|
Formulary
|
|
CKS guideline: Management of confirmed endometriosis - Secondary Care treatments
|
Triptorelin (Decapeptyl SR®)
|
Formulary
|
|
CKS guideline: management of confirmed endometriosis - Secondary Care treatements
|
Triptorelin (Salvacyl®)
|
Formulary
|
|
CKS guideline: management of confirmed endometriosis - Secondary Care treatements
|
06.07.02 |
Breast pain (mastalgia) |
|
|
06.07.03 |
Metyrapone |
|
|
06.07.04 |
Somatomedins |
|
|
.... |
Non Formulary Items |
Acarbose (tablets)
|
Non Formulary
|
|
|
Acarbose (Glucobay®) (tablets)
|
Non Formulary
|
For existing patients ONLY |
|
Alendronic Acid (Oral solution)
|
Non Formulary
|
Removed from formulary in Decemeber 2016, replaced by effervescent tablets |
|
ALENDRONIC ACID
|
Non Formulary
|
ALENDRONIC ACID / Fosamax Once Week - Black
ALENDRONIC ACID/COLECALCIFEROL - Black
ALENDRONIC ACID/COLECALCIFEROL / Bentexo - Black
ALENDRONIC ACID/COLECALCIFEROL / Fosavance - Black |
|
Alendronic Acid (Fosamax®)
|
Non Formulary
|
|
|
Alendronic Acid (Fosamax® Once Weekly)
|
Non Formulary
|
|
|
Alendronic Acid with colecalciferol (Fosavance®)
|
Non Formulary
|
|
|
Armour thyroid
|
Non Formulary
|
|
Patient Information: Changes to liothyronine prescribing
UKMI Q&A: What clinical evidence is there to support the use of desiccated thyroid extract products?
|
Bazedoxifene/Conjugated Oestrogens (Duavive®)
|
Non Formulary
|
|
BMS- guidance on HRT prescribing
|
Biphasic Isophane Insulin (Hypurin Porcine 30/70 Mix®)
|
Non Formulary
|
|
|
Biphasic Isophane Insulin (Mixtard® 30)
|
Non Formulary
|
|
|
Buserelin
|
Non Formulary
|
Black - Suprecur
Black - Suprefact
Black - Nasal Spray |
NICE CG156: Fertility problems: assessment and treatment
|
CALCITRIOL (Rocaltrol®)
|
Non Formulary
|
|
|
Captopril
|
Non Formulary
|
|
|
Carbamazepine
|
Non Formulary
|
Diabetic neuropathy |
|
Cetrorelix (Cetrotide®)
|
Non Formulary
|
|
|
Chlorpropamide
|
Non Formulary
|
|
|
CHLORTALIDONE
|
Non Formulary
|
Hylaton - Black |
|
Climagest
|
Non Formulary
|
|
|
Climaval®
|
Non Formulary
|
|
|
Clonidine (Oral Solution)
|
Non Formulary
|
|
|
Combination test strips
|
Non Formulary
|
|
|
Corifollitropin Alfa (Elonva®)
|
Non Formulary
|
|
|
Cortisone Acetate
|
Non Formulary
|
|
|
Cyclo-Progynova®
|
Non Formulary
|
|
|
Deflazacort (Calcort®)
|
Non Formulary
|
|
|
Demeclocycline (tablets)
|
Non Formulary
|
|
|
DESMOPRESSIN
|
Non Formulary
|
- Nasal Drops
- Noqdirna oral lyophilisate
|
|
Dexamethasone (Glensoludex®)
|
Non Formulary
|
|
Primary care summary - Dexamethasone in the treatment of COVID-19
|
Diazoxide
|
Non Formulary
|
|
|
Dienogest
|
Non Formulary
|
BRANDS
|
|
Disodium Eitdronate (Didronel PMO®)
|
Non Formulary
|
|
|
Disodium Etidronate (Didronel®)
|
Non Formulary
|
|
|
Duloxetine
|
Non Formulary
|
- Cymbalta
- Depalta
- Duciltia
- Yentreve
|
|
Dydrogesterone (Duphaston®)
|
Non Formulary
|
|
|
Dysrogesterone (Duphaston® HRT)
|
Non Formulary
|
|
|
Estradiol with progesterone continuous tablets for HRT (Angeliq®)
|
Non Formulary
|
|
|
ESTRADIOL/PROGESTERONE (Bijuve®)
|
Non Formulary
|
|
|
FINASTERIDE (1mg Tablet)
|
Non Formulary
|
BNF states - Finasteride is not prescribable in NHS primary care for the treatment of androgenetic alopecia in men. |
|
Follitropin Beta (Puregon®)
|
Non Formulary
|
|
|
Follitropin Alfa
|
Non Formulary
|
Bemfola - Black
Gonal-F - Black
Ovaleap - Black
Puregon - Black
|
|
FOLLITROPIN ALFA / LUTROPIN ALFA
|
Non Formulary
|
Pergovis Powder/Solvent - Black |
|
FOLLITROPIN DELTA
|
Non Formulary
|
Rekovelle - Black |
|
Ganorelix (Orgalutran®)
|
Non Formulary
|
|
|
Gestrinone (Demetriose®)
|
Non Formulary
|
|
|
Glipizide
|
Non Formulary
|
|
|
Gliquidone (Glurenorm®)
|
Non Formulary
|
|
|
Glucose
|
Non Formulary
|
- Clinistix
- Clinitest
- Diabur-Test 5000
- Diastix
- Diastix testing strips
- Element testing strips blood glucose testing strips
- Finetest Lite testing strips blood glucose testing strips
- Medi-Test Glucose testing strips urine glucose testing strips
- MediSense SoftSense testing strips blood glucose testing strips
- MediTouch 2 testing strips blood glucose testing strips
- MediTouch testing strips blood glucose testing strips
- Mendor Discreet testing strips blood glucose testing strips
|
|
Hormonin®
|
Non Formulary
|
|
|
Human Menopausal Gonadotrophins (Menogon®)
|
Non Formulary
|
|
|
Hydrocortisone
|
Non Formulary
|
- Modified Release
- Plenadren
|
|
Insulin
|
Non Formulary
|
- Hypurin Porcine Neutral
- Insuman Infusat
|
|
Insulin (Exubera®)
|
Non Formulary
|
|
|
Insulin (Pork Actrapid®)
|
Non Formulary
|
|
|
Insulin (Velosulin®)
|
Non Formulary
|
|
|
Insulin bovine (Hypurin® Bovine Neutral)
|
Non Formulary
|
For existing patients only
Discontinued July 2017 |
|
Insulin degludec with insulin aspart (DegludecPlus)
|
Non Formulary
|
|
|
Insulin glargine 100units/ml (Abasaglar ®)
|
Non Formulary
|
Cost price is more than originator April 2023 DM+d and DT Abasaglar (£35.28); Lantus (£34.75) |
NICE NG17: Type 1 diabetes in adults: diagnosis and management
|
INSULIN GLARGINE/LIXISENATIDE
|
Non Formulary
|
|
|
Insulin Pen Needles (TRICARE®)
|
Non Formulary
|
|
|
Insulin porcine (Hypurin Porcine Neutral®)
|
Non Formulary
|
Black from 28/11/23 -Continue in historic patients |
|
Insulin Zinc suspension (Hypurin®Bovine Lente)
|
Non Formulary
|
For existing patients only
Discontinued July 2017 |
|
Irbesartan
|
Non Formulary
|
|
|
Isophane Insulin (Hypurin Bovine Isophane®)
|
Non Formulary
|
|
|
Isophane Insulin (Hypurin Porcine Isophane®)
|
Non Formulary
|
For existing patients only |
|
Isophane Insulin (Pork Insulatard®)
|
Non Formulary
|
|
|
Ketones test strips
|
Non Formulary
|
- 4SURE beta-ketone testing strips
- Fora Advanced pro GD40 Ketone testing strips
- FreeStyle Optium H beta-ketone testing strips
- FreeStyle Precision Pro beta-ketone testing strips
- GlucoMen areo Ketone Sensor testing strips
- GlucoRx HCT Ketone testing strips
- Ketur Test
- StatStrip beta-ketone testing strips
- Xceed Precision Pro beta-ketone testing strips
|
|
LEUPRORELIN ACETATE (Staladex)
|
Non Formulary
|
|
|
Levothyroxine
|
Non Formulary
|
- Eltroxin
- Capsule
- Oral solution
|
|
Lisinopril (Zestril®)
|
Non Formulary
|
|
|
Losartan Potassium (Cozaar® )
|
Non Formulary
|
|
|
Lucozade
|
Non Formulary
|
|
|
Lutropin Alfa
|
Non Formulary
|
Luveris - Black
Luveris Powder/Solvent - Black |
|
Mecasermin (Increlex®)
|
Non Formulary
|
|
|
MENOTROPHIN
|
Non Formulary
|
BRANDS
- Menopur powder/solvent
- Meriofert powder/solvent
|
|
Mesterolone (Pro-Viron®)
|
Non Formulary
|
|
|
Methylprednisolone
|
Non Formulary
|
ACETATE INJECTION
SODIUM SUCCINATE INJECTION
- Depo-Medrone
- Medrone
- Solu-Medrone
- Depo-Medrone
- Solu-Medrone
|
|
Methylprednisolone (Oral presentations)
|
Non Formulary
|
|
|
Nadolol
|
Non Formulary
|
|
|
Nafarelin
|
Non Formulary
|
Synarel |
|
Nateglinide (Starlix®)
|
Non Formulary
|
For existing patients ONLY |
|
Norethisterone (Micronor®HRT)
|
Non Formulary
|
|
|
NORISTERAT INJECTION
|
Non Formulary
|
|
|
Nuvelle Continous tablets
|
Non Formulary
|
|
|
OESTROGENS FOR HRT (Bedol®)
|
Non Formulary
|
https://thebms.org.uk/publications/tools-for-clinicians/
|
|
OSILODROSTAT
|
Non Formulary
|
|
|
OXANDROLONE 2.5 MG
|
Non Formulary
|
|
|
PARATHYROID HORMONE
|
Non Formulary
|
Preotact - BLACK |
|
Pasireotide (Signifor®)
|
Non Formulary
|
|
|
Pegvisomant
|
Non Formulary
|
Somavert - Black
Somavert Powder/Solvent - Black |
|
Pioglitazone (Actos®)
|
Non Formulary
|
Pioglitazone should not be used in people who have heart failure or who are at higher risk of fracture. Continue Pioglitazone therapy only if there is a reduction of ≥0.5 percentage points in HbA1c in 6 months. Monitor for liver toxicity. There is risk of bladder cancer with pioglitazone. Do not use in active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Assess risks for bladder cancer after 3-6months of starting pioglitazone. Refer to current BNF for full contraindications and interactions. |
MHRA: Insulin combined with pioglitazone: risk of cardiac failure
MHRA: Pioglitazone: risk of bladder cancer
TA63: Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21)
|
Pioglitazone and Metfomin
|
Non Formulary
|
|
|
Prednisolone M/R
|
Non Formulary
|
|
|
Primolut N®
|
Non Formulary
|
|
|
PROGESTERONE
|
Non Formulary
|
BRANDS
|
|
Progesterone Injection (Gestone®)
|
Non Formulary
|
|
|
Protamine Zinc Insulin (Hypurin® Bovine Protamine Zinc)
|
Non Formulary
|
For existing patients only
Discontinued July 2017 |
|
Protein test strips (Medi-Test Protein 2 ®)
|
Non Formulary
|
in Primary care,
Secondary care to discuss with pathology |
|
RISEDRONATE 5MG
|
Non Formulary
|
|
|
Risedronate Sodium (Actonel®)
|
Non Formulary
|
Actonel - Black
RISEDRONATE/CALCIUM CARBONATE/COLECALCIFEROL - Black
RISEDRONATE/CALCIUM CARBONATE/COLECALCIFEROL / Actonel Combi - Black
|
UKMI Q&A: Can oral bisphosphonates be given to people with renal impairment to treat osteoporosis?
MHRA: Bisphosphonates: atypical femoral fractures
NICE TA464: Bisphosphonates for treating osteoporosis
TA 161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
|
Rosglitazone (Avandia®)
|
Non Formulary
|
|
|
Rosiglitazone and Metformin (Avandamet)
|
Non Formulary
|
|
|
Saxagliptin
|
Non Formulary
|
|
|
Saxagliptin and Dapagliflozin
|
Non Formulary
|
|
|
Saxagliptin and Metformin
|
Non Formulary
|
|
|
Sermorelin (Geref 50®)
|
Non Formulary
|
|
|
Sitagliptin (Januvia®)
|
Non Formulary
|
|
MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
|
Test Strips
|
Non Formulary
|
BRANDS
- 4SURE testing strips
- Accu-Chek Inform II testing strips
- Active testing strips
- Advocate Redi-Code+ testing strips
- AutoSense testing strips
- BGStar testing strips
- Betachek C50 cassette
- Betachek G5 testing strips
- Betachek Visual testing strips
- Breeze 2 testing discs
- CareSens N testing strips
- Contour TS testing strips
- Contour testing strips
- Dario Lite testing strips
- Dario testing strips
- Element testing strips
- Finetest Lite testing strips
- Fora Advanced pro GD40 testing strips
- FreeStyle Lite testing strips
- FreeStyle Optium H testing strips
- FreeStyle Optium Neo H testing strips
- FreeStyle Precision Pro testing strips
- FreeStyle testing strips
- GluNEO testing strips
- GlucoDock testing strips
- GlucoLab testing strips
- GlucoRx GO Professional testing strips
- GlucoRx GO testing strips
- GlucoRx HCT Glucose testing strips
- GlucoRx Nexus testing strips
- GlucoRx Q testing strips
- GlucoRx Vivid testing strips
- GlucoZen.auto testing strips
- Glucofix Tech Sensor testing strips
- Glucoflex-R testing strips
- Guide testing strips
- Kinetik Wellbeing testing strips
- MODZ testing strips
- MediSense SoftSense testing strips
- MediTouch 2 testing strips
- MediTouch testing strips
- Mendor Discreet testing strips
- Microdot Max testing strips
- Microdot+ testing strips
- Myglucohealth testing strips
- Mylife Aveo testing strips
- Mylife Pura testing strips
- Mylife Unio testing strips
- OKmeter Core testing strips
- Oh'Care Lite testing strips
- On Call Sure testing strips
- On-Call Advanced testing strips
- OneTouch Select Plus testing strips
- OneTouch Verio testing strips
- Performa testing strips
- SD CodeFree testing strips
- SURESIGN Resure testing strips
- Sensocard testing strips
- StatStrip testing strips
- TRUEyou testing strips
- True Metrix testing strips
- VivaChek Ino testing strips
- Xceed Precision Pro testing strips
- palmdoc iCare Advanced Solo testing strips
- palmdoc iCare Advanced testing strips
- palmdoc testing strips
|
|
TESTOSTERONE ENANTATE
|
Non Formulary
|
|
|
TESTOSTERONE IMPLANTS
|
Non Formulary
|
|
|
Tiludronic Acid (Skelid®)
|
Non Formulary
|
|
|
Triamcinolone
|
Non Formulary
|
TRIAMCINOLONE ACETONIDE
- Adcortyl Intra-articular / Intradermal
- Kenalog
- Nasacort
|
|
Trilostane (Modrenal®)
|
Non Formulary
|
|
|
TRIPTORELIN (Gonapeptyl Depot)
|
Non Formulary
|
|
|
TRISEQUENS S
|
Non Formulary
|
|
|
ULIPRISTAL ACETATE
|
Non Formulary
|
|
|
Ulipristal acetate (Esmya®)
|
Non Formulary
|
MHRA March 2020 Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury
July 2018 - Traffic light status amended to RED in light of EMA update
Esmya: new measures to minimise risk of rare but serious liver injury
The only indication approved for use by the APC is pre-operative treatment of moderate to severe symptoms of uterine fibroids (1 course). |
EMA June 2018: Esmya: new measures to minimise risk of rare but serious liver injury
MHRA February 2018: Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users
|
Urinalysis (Clinitest®)
|
Non Formulary
|
Black in Primary care
Secondary care to discuss with pathology |
|
Urinalysis test strips glucose Mission Glucose®
|
Non Formulary
|
|
|
Urine Ketone Testing strips
|
Non Formulary
|
BRANDS
Black in Primary Care, secondary care to discuss with pathology
- GlucoRx KetoRx Sticks 2GK testing strips
- Ketostix testing strips
|
|
Urine Protein Testing Strips
|
Non Formulary
|
Black in Primary Care, secondary care to discuss with pathology |
|
Urofollitropin
|
Non Formulary
|
Fostimon powder/solvent - Black |
|
Utrogestan® Vaginal Capsules
|
Non Formulary
|
|
|
Vildagliptin
|
Non Formulary
|
|
|
Vildagliptin/ Metformin
|
Non Formulary
|
|
|
|
Key |
|
Restricted Drug |
|
Unlicensed |
|
Link to adult BNF
|
|
Link to children's BNF
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
|